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AcyI-plasmin-streptokinase compIex has advantages as a ‘site’ directed fibrinolytic agent with the active site 
protected from the plasma protease inhibitors. But, in clinical use. the fibrinolytic potential of this acylq 
enzyme complex is modified or abolished by the presence of strcptnkinase antibodies in the patients. There- 
fore, better therapeutic agents are required. In this work, chemical modification of the acyl-plnsmin-strepto- 
k&se complex with pdyethylene giycaf was found to result in marked resistance to ~~~tra~~zafion with
I + INTRODIJCTION 
The treatment of deep vein t~r~rnbos~~ with cur- 
rent@ a~ai$abfe thrombo~~i~ drugs, st~~~toki~ase 
and urokinase, is not very satisfactory. The major 
problem with streptokinase as a t~~ornbo~yt~~ 
agent is the induced hemostatic defect lending to 
severe and life-threatening or fatal hem.orrhage 
and a new approach to this problem has been 
reported f If. 
BRL 2621 is 51 novef tbrombo~~i~ agent in 
which streptokinase-p~~rnino~en ~~~~~~~ is 
chemicaify modified by acyjation at the c&tafytie 
center of its plasmin moiety. Because the fibrin- 
binding site of the complex and its catalytic center 
are functionally separate, the acylated complex can 
bind to fibrin and is protected from the normal 
plasma protease i~~~itors [I]. This complex has 
been shown to be a potent and specific throm- 
bob&c agent in rabbits and dogs with ~~~~irn~nta~ 
venous thrombosis III. 
In patients with acute myocardial infarction, 
Walker et al. [2] found that the complex was well 
tolerated and produced no serious bleeding when 
adrn~~i~t~r~ into a ~oror~~~~ artery to patients 
with doses of BRL 26921 aging 5 to 25 mg, 
a~tho~~~ it appeared less ‘selective&’ tbrorn~o~~~~ 
in ~~t~~~ts than had been ~?xpected from animal 
models, They also found that the degree of in- 
duced systemic fibrinolytic activation was modified 
by the presence of streptokinase antibodies. 
In healthy volunteers [3j and in patients with 
deep vein occlusion $41, it ha,s been shown that add- 
ministration of a~y~-pfasmi~ogen-streptokinasc3 
complex (or pfasminogetn-sSre~tokinase ~orn~~~~~ 
induces anamnestic rise in st~~~tokinase antibodies 
which neutralize the actian of enzyme complex. 
Matsuo et al. [5] investigated the influence of 
streptokinase antibodies on the fibrinolytic and 
fibri~~~~~oiyti~ activity of EIRL 26921 and re- 
ported that high titers of ~~~~~tukinase antibodies 
abo~sb~ the effect of the agent, 
In c&&c& use, therefore, it is important to take 
account of the patient% pretreatment stre~tok~~~s~ 
resistance. 
This study was designed to prepare a new class 
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of thrombolytic agents, acyl-plasmin-streptokinase 
complex derivatives, of which the fibrinolytic 
potential is not influenced by streptokinase an- 
tibodies present in the patients. 
2. MATERIALS AND METHODS 
2.1. Reagents 
Purified streptokinase (EC 3.4.99.22; kabikinase) 
and human fibrinogen (grade L) were purchased 
from Kabi Vitrum AB (Stockholm). Monomethoxy- 
polyethylene glycol (n/i, 5000) was from Aldrich 
(USA). Synthetic fluorogenic substrate, Boc-Val- 
Leu-Lys-MCA, was from Peptide Institute, 
(Osaka, Japan). 
2.2. Acyl-piasmin-streptokinase complex 
Human plasminogen was activated by incuba- 
tion with a catalytic amount of streptokinase. 
Plasmin was further purified by affinity chroma- 
tography on a soybean trypsin inhibitor-immo- 
bilized Sepharose 4B column. Purified plasmin 
was acylated with ~nitrophenyI-p f -guanidinoben- 
zoate. Acyl-plasmin (31 mg) was absorbed on an 
L-lysine-Sepharose column and washed with 0.1 
mM p-nitrophenyl-p’ -guanidinobenzoate/SO mM 
sodium phosphate buffer (pH 7.4). Streptokinase 
(26 mg) was applied to the column and washed 
with the same buffer. Acyl-plasmin-streptokinase 
complex was obtained by elution with the same 
buffer containing 0.2 M .+aminocaproic acid. This 
acyl-piasmin-streptokinase complex was shown to 
consist of equimolar amounts of acyl-plasmin (Mr 
85 000) and streptokinase (MI 47400) by SDS- 
polyacrylamide gel electrophoresis (not shown). 
2.3. modification with monomet~oxypoIyet~y~e~e 
giycol 
Acyl-plasmin-streptokinase complex was modi- 
fied as in 161. Monomethoxypolyethylene glycol 
(15 g) was coupled with cyanuric chloride (0.55 g) 
to form 2-o-methoxypolyethylene glycol-4,6-di- 
chloro-s-triazine. To an acyl-plasmin-streptokinase 
complex soIution (5 mg) in 0.5 M tetramethylam- 
monium hydroxide/O. 1 mM p-nitrophenyl-p’ - 
guanidinobenzoate/50 mM sodium phosphate buf- 
fer f&H 7.4), activated polyethylene glycol was 
added. The mixture was incubated for 30 min at 
4°C. Then excess activated polyethylene glycol was 
removed by ultrafiltration with an XM-50 mem- 
brane (Amicon). Acyl-plasmin-streptokinase com- 
plexes with various degrees of modification were 
prepared using different molar ratios of activated 
polyethylene glycol (PEG) to amino groups in the 
acyl-enzyme molecule (PEG/-NH*: 1.0, 3.0 and 
10.0). The extents of modification of amino 
groups in the molecule were determined by 
measuring the amounts of free amino groups with 
trinitrobenzenesulfonate [7]. 
Protein concentrations were determined by the 
biuret method [S]. 
2.4. Dea~ylatio~ of the acy~-piasmin-streptokinase 
complex 
The native (50 pg) and modified complexes (50 
pg) were incubated in 1 ml of 100 mM L-lysine/lOO 
mM NaCl/SO mM Tris-HCI (pH 8.0) at 37°C. 
2.5. Plasminogen activator activity 
Plasminogen activator activities of the deacylated 
native and modified enzyme complexes were 
assayed with a synthetic fluorogenic substrate, 
Boc-Val-Leu-Lys-MCA, as follows [9]: enzyme 
complexes (0.5 pg) were preincubated with 50 pg 
human plasminogen in 1 ml of 20 mM L-lysine/lOO 
mM NaCI/SO mM Tris-HCl (pH 8.0) for 10 min at 
37°C. Then, 1 ml of 0.1 mM Boc-Val-Leu-Lys- 
MCA was added and incubated for 20 min at 
37°C. The liberated 7-amino-4-methylcoumarin 
(AMC) was measured fluorometrically with excita- 
tion at 380 nm and emission at 460 nm. Under 
these conditions, streptokinase showed a specific 
activity of 10 pmol AMC/min per mg. 
2.6. Neutralization of plasminogen activator 
activity 
After incubation for 8 h under the above condi- 
tions to generate enzyme activity, the native and 
modified enzyme complexes (0.5 pg) were in- 
cubated with streptokinase antibodies (O-O+4 mg) 
in 1 ml of 20 mM L-lysine/lOO mM NaCl/SO mM 
Tris-HCl (pH 8.0) at 37’C for 20 min. Then, re- 
maining plasminogen activator activity was mea- 
sured with the synthetic substrate as described 
above. 
2.7. Fibrinolytic activity 
The fibrin clot lysis activities of native and 
modified acyl-plasmin-streptokinase complexes 
were determined by incubating them (220 pg) in 5 
45 
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ml normal human serum (streptokinase antibody 
titer 25 units per ml) at 37°C with a fibrin clot, 
which was prepared in a silicon-coated glass tube 
(4 2.4x20 mm) from human fibrinogen and 
human thrombin. After incubation for 6 h, lysis of 
the fibrin clot was determined by measuring the 
length of the fibrin clot. A standard curve was 
prepared with various amounts of streptokinase. 
Streptokinase antibody titers were determined as 
described by Amery et al. [lo]. 
2.8. Streptokinase antibodies 
Anti-streptokinase serum was obtained from rab- 
bits immunized 5 times by subcutaneous injection 
of streptokinase (5 mgx 5). Streptokinase anti- 
bodies were obtained from antiserum by (NH&- 
SO4 precipitation and DE-52 chromatography. 
3. RESULTS AND DISCUSSION 
The acyl-plasmin-streptokin~e complex has the 
proposed advantages as a site directed fibrinol~ic 
agent with the active site protected from normal 
plasma protease inhibitors of plasmin. Since the 
active site of the acyl-enzyme complex is blocked, 
there is little residual enzymic activity. But the acyl 
moiety can be released by deacylation. Thus, if an 
acyl-plasmin-streptokinase complex is applied to 
an assay of fibrinolytic activity, the release of 
plasmin-streptokinase complex by deacylation 
would be expected to lead to fibrinolysis. Fig.1 
shows the deacylation of the native and modified 
complexes after incubation at 37°C. The degree of 
generation of plasminogen activator activity was 
influenced by .polyethylene glycol modification. 
The generated activator activity of native enzyme 
complex rapidly decreased with time of incubation 
(curve A), while the activities of the modified en- 
zyme complexes were more stable (curves B-D). 
These results suggest hat polyethylene glycol pro- 
tects the complexes from proteolytic inactivation. 
This conclusion is consistent with the findings that 
modification of catalase [I l] and L-asparaginase 
(121 with polyethylene glycol result in their resis- 
tance to proteolytic digestion. 
These generated plasminogen activator activities 
of the modified complexes showed marked resis- 
tance against neutralization with streptokinase an- 
tibodies (fig.2). After incubation for 8 h at 37OC to 
generate enzyme activity, the native (curve A) and 
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Fig.1. Deacylation of native and polyethylene glycol- 
modified acyl-plasmin-streptokinase complexes after in- 
cubation. Curves: A (o), native complex; B (0), modi- 
fied complex (26.2% modification); C (a), modified 
complex (5’7.5%); D (A), modified complex (68.6To). 
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Fig.2. Effect of streptokinase antibodies on plasminogen 
activator activities of native and polyethylene glycol- 
modified acyi-plasmin-streptokinase complexes. Curves: 
A (o), native complex; B (0). modified complex (26.2% 
modification); C fm), modified complex (57.5%); D (A), 
modified complex (~.6~0). 
modified (curves B-D) complexes were incubated 
with various amounts of streptokinase antibodies 
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at 37°C for 20 min and then remaining plasmin- 
ogen activator activity was measured with the syn- 
thetic substrate. The incubation with antibodies 
resulted in the reduction of the activator activity of 
native complex (400’/0), while the polyethylene 
glycol-modified complexes, in which 57.5% (curve 
C) and 68.6% (curve D) of the amino groups in the 
native complex had been modified, showed com- 
plete resistance to neutralization with strep- 
tokinase antibodies. Streptokinase showed com- 
plete loss of enzymic activity on incubation with 
0.4 mg streptokinase antibodies (not shown). 
The fibrin clot lysis activities of the polyethylene 
glycol modified acyl-plasmin-streptokinase com- 
plexes were determined in human serum (strep- 
tokinase antibody titer 25 units per ml) (table 1). 
Increasing the degree of modification of amino 
groups with polyethylene glycol resulted in the 
reduction of fibrinolytic activity. The modified 
acyl-plasmin-streptokinase complex in which 
57.5% of the amino groups in the native complex 
were substituted showed 40% of the activity of the 
native complex. Although, we have not assessed 
the fibrinolytic potential of this material in human 
serum which had high titers of streptokinase an- 
tibodies, it is suggested that this material should 
show no reduction of the fibrinolytic activity with 
antibodies in human serum or plasma, from the 
results described in fig.2. 
The fibrinolytic activity of acyl-plasminogen- 
streptokinase complex, BRL 26921, has been 
shown to be abolished in human plasma with high 
titers of streptokinase antibodies [5]. They had in- 
vestigated the fibrinolytic activity of BRL 26921 at 
a final concentration of 100 units per ml in normal 
plasma (streptokinase antibody titer 25 units per 
ml) and plasma obtained from a patient 3 weeks 
Table 1 
Fibrinolytic activities of the polyethylene glycol 
modified acyl-plasmin-streptokinase complexes 
Sample 
Native complex 
Modified complex 
Modified complex 
Modified complex 
Modification Fibrinolytic 
degree (vo) activity (vo) 
0 100 
26.2 71 
57.5 40 
68.6 10 
after treatment with streptokinase (streptokinase 
antibody titer 610 units per ml) and reported that 
high titers of streptokinase antibodies abolished 
the effect of BRL 26921 [5]. 
In healthy volunteers [3] and in patients with 
deep vein occlusion [4], it has been shown that ad- 
ministration of acyl-plasminogen-streptokinase 
complex (or plasminogen-streptokinase complex) 
induces anamnestic rise in streptokinase antibodies 
which neutralize the action of these agents. In 
clinical use, therefore, it is essential to take ac- 
count of the patient’s pretreatment neutralizing 
antibody, because until this neutralizing antibody 
is exceeded no fibrinolysis will take place in the pa- 
tient . 
The preparation of polyethyelene glycol modi- 
fied acyl-plasmin-streptokinase complex reported 
here showed: (i) generation of plasminogen ac- 
tivator activity by deacylation; (ii) fibrinolytic ac- 
tivity in human serum; (iii) complete resistance to 
neutralization with streptokinase antibodies. 
Because of its low sensitivity to the neutralizing an- 
tibody, we believe that the polyethyelene glycol- 
modified acyl-plasmin-streptokinase complex 
should be useful for treating patients who have 
high titers of streptokinase antibodies, in par- 
ticular, those who had previous streptokinase 
treatment. 
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